ANI Pharmaceuticals (NASDAQ:ANIP) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Other analysts also recently issued reports about the company. HC Wainwright increased their price objective on ANI Pharmaceuticals from $50.00 to $53.00 and gave the company a “buy” rating in a report on Monday, March 13th. Guggenheim assumed coverage on ANI Pharmaceuticals in a report on Tuesday, February 28th. They issued a “buy” rating and a $55.00 price objective for the company. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $39.35 on Thursday. The company has a market capitalization of $687.25 million, a price-to-earnings ratio of -12.94 and a beta of 1.06. ANI Pharmaceuticals has a twelve month low of $22.31 and a twelve month high of $45.99. The stock has a fifty day simple moving average of $42.99 and a 200 day simple moving average of $39.14. The company has a quick ratio of 2.40, a current ratio of 3.46 and a debt-to-equity ratio of 0.91.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Swiss National Bank boosted its position in ANI Pharmaceuticals by 9.6% during the second quarter. Swiss National Bank now owns 29,600 shares of the specialty pharmaceutical company’s stock valued at $878,000 after acquiring an additional 2,600 shares during the last quarter. Public Sector Pension Investment Board boosted its position in ANI Pharmaceuticals by 2.1% during the second quarter. Public Sector Pension Investment Board now owns 24,249 shares of the specialty pharmaceutical company’s stock valued at $719,000 after acquiring an additional 499 shares during the last quarter. Cullen Capital Management LLC boosted its position in shares of ANI Pharmaceuticals by 29.1% during the 3rd quarter. Cullen Capital Management LLC now owns 13,709 shares of the specialty pharmaceutical company’s stock worth $441,000 after purchasing an additional 3,086 shares in the last quarter. High Note Wealth LLC bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth about $221,000. Finally, Ergoteles LLC bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth about $369,000. Institutional investors own 67.89% of the company’s stock.

ANI Pharmaceuticals Company Profile

(Get Rating)

ANI Pharmaceuticals, Inc is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.